We evaluated the efficacy and safety of ceftriaxone in 50 adults with serious infections, usually giving 1 g every 12 h. Of the 35 patients who could be evaluated for clinical efficacy, 15 had failed on previous therapy, 15 had nosocomial infections, and all but 1 had underlying diseases. One patient had three sites of infection. Favorable responses were seen in 34 of 37 infections, including 11 of 13 respiratory tract infections, all 7 urinary tract infections, all 12 skin and soft tissue infections, 1 of 2 bone and joint infections, a catheter-related septicemia, a liver abscess, and an otitis media and externa. Favorable bacteriological responses were seen for 48 of 58 organisms. This included 6 of 7 Staphylococcus aureus strains, 14 of 16 other aerobic gram-positive cocci, 18 of 20 Enterobacteriaceae, 6 of 9 Pseudomonas aeruginosa, and 1 of 2 anaerobes. Peak plasma ceftriaxone levels on day 1 were 152 ,ug/ml by bioassay and 78 ,ug/ml by high-pressure liquid chromatography. Four of the 31 initial isolates of aerobic gram-negative rods developed resistance to ceftriaxone on disk diffusion testing. Diarrhea occurred in 3 of 50 patients. All three had received a higher than usual dose. Drug administration was stopped twice, once for a thrombocytopenia and once for a thrombocytopenia with leukopenia. Neither problem could be attributed exclusively to ceftriaxone. Other adverse reactions were eosinophilia, abdominal pain, inguinal candidiasis, and nonsuppurative phlebitis. Even among debilitated adults, ceftriaxone was safe and effective in a twice daily regimen.
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Ceftriaxone is a new broad-spectrum cephalosporin active in vitro against a wide range of aerobic and anaerobic gram-positive and gramnegative bacteria (1, 3, 5) . Ninety percent of Staphylococcus aureus isolates are inhibited by 3.1 ,ug/ml, Streptococcus pneumoniae by 0.25 jig/ml, Haemophilus influenzae by 0.01 ,.g/ml, most Enterobacteriaceae by 0.2 jig/ml, Serratia marcescens and Bacteroides fragilis by 25 Fg/ml, and Pseudomonas aeruginosa by 50 ,ug/ml (5) . As a single chemotherapeutic agent, ceftriaxone would be expected to be effective in the treatment of a broad range of bacterial infections when given as infrequently as twice daily, since the half-life in healthy subjects is 6 to 8 h and peak plasma levels of 150 ;.g/ml can be achieved after a 1-g intravenous dose (6, 9) . Therefore, we evaluated its efficacy and safety in a population of debilitated, hospitalized adults with acute, serious infections requiring systemic antimicrobial therapy. Urinary tract infections were designated as reinfected when the original uropathogen was eliminated but when a recurrent infection with another species occurred. A bacteriological failure was defined as the persistence of the initial pathogen at the completion of a course of ceftriaxone.
RESULTS
Patient characterstics. Although 37 men and 13 women were enrolled, 15 were excluded from evaluation of efficacy. They were evaluated only for ceftriaxone levels and toxicity. Failure to isolate a susceptible pathogen from pretreatment culture excluded seven patients. Four were excluded because they lacked indicated follow-up cultures, two because of administration of subsequent antimicrobial agents obscuring followup, one because of administration of concomitant antimicrobial agents expected to be effective against the infecting pathogen, and one because therapy was given for less than 3 days.
The remaining 26 men and 9 women ranged in age from 18 to 90, with a mean of 60. Nearly all (34 of 35) had underlying disease, 15 had failed on other therapy as manifest by positive posttreatment cultures, and 15 had nosocomial infections. None was leukemic or leukopenic, but one was receiving azathioprine and prednisone for giant cell arteritis.
Twenty-six of the 35 patients received 1 g of ceftriaxone every 12 h. This dose was reduced to 250 mg every 12 h in one patient (patient 33) who developed uremia due to hypotension, sepsis, and aminoglycoside treatment. Larger doses delivered at more frequent intervals (up to 2 g every 6 h) were given to two patients with P. aeruginosa infections and to six patients with infected foot ulcers. Twenty-nine patients received a 5-to 15-day course of therapy. Three individual patients with foot ulcer, anaerobic empyema, and osteomyelitis, respectively, received 20-to 43-day courses. In two patients, courses were shortened to 3 to 4 days; this was a result of suspicions of clinical failure (which were not confirmed). A Single pathogens were isolated in 24 of the 37 infections, including all urinary tract infections and bacteremias. At least two organisms were isolated from 3 of 13 respiratory infections, 5 of 7 foot ulcers, 2 of the 5 cases of cellulitis, and the arthritis, the liver abscess, and the otitis media and externa. Five organisms were isolated from secretions suctioned from the endotracheal tube of a patient (patient 4) with aspiration pneumonia and five from synovium of the arthritis patient (patient 31).
All tested aerobic isolates were susceptible to ceftriaxone on disk diffusion testing. For five aerobic isolates, bacteriological success was obtained, but susceptibility results were not available. The two anaerobic isolates were susceptible by broth diffusion or disk diffusion testing.
Ceftriaxone levels. St. Paul-Ramsey Medical Center plasma ceftriaxone levels measured by bioassay (mean ± standard deviation) were less on day 1 for 17 patients (peak, 152.5 ± 91. 4 ,ug/ml; trough, 26 ± 15.9) than for the 13 patients studied on day 4 (peak, 179.2 ± 105.6; trough, 36.3 ± 28.9). Similarly, in Omaha, day 1 peak levels measured by high-pressure liquid chromatography among 15 patients were 78.5 ± 44.9 with day 1 troughs among 13 patients of 40.2 ± 15.9. Among the 11 Omaha patients studied on day 4, the peak was 142.5 ± 40.6, and the trough was 62.7 ± 30.4 (Fig. 1) .
In one patient, cerebrospinal fluid ceftriaxone levels were 14.8 and 32.9 ,ug/ml as measured by high-pressure liquid chromatography. Response (iv) Bone and joint infections. A patient with traumatic osteomyelitis in whom tobramycin had failed (patient 32) responded to ceftriaxone. However, Enterobacter cloacae persisted in a patient (patient 31) who had arthritis of the knee.
(v) Bacteremias. Two patients were bacteremic: patient 2 with pneumococcal pneumonia and patient 33 with an infected intravenous catheter. Both cleared their bacteremias on ceftriaxone.
(vi) Miscellaneous infections. Other infections responding to ceftriaxone included a nosocomial liver abscess from which Enterobacter agglomerans and P. aeruginosa were isolated, which had failed to respond to gentamicin and vancomycin. The E. agglomerans was eradicated with ceftriaxone but the P. aeruginosa persisted, and other antibiotics were required. In addition, one patient with gram-negative otitis media and extema which had failed on topical neomycin was successfully treated.
Emergence of resistance among gram-negative bacilli. Among 24 patients who could be evaluated, from whom a total of 31 isolates of aerobic gram-negative bacilli were recovered, 18 isolates were eradicated. In one patient with a healing P. aeruginosa osteomyelitis, attempts were not made to reculture the organism. Of the 12 isolates that were recovered on repeat culture, 7 remained susceptible on disk diffusion testing, and testing was omitted in 1. Thus, emergence of resistance during therapy occurred in only four cases, two of which involved P. aeruginosa. In one, the initial zone diameter decreased from 20 to 6 mm (patient 30), and in another (patient 9), the zone size decreased from 18 to 12 mm and, subsequently, to no inhibition. Yet, in both cases clinical improvement ensued, and antimicrobial agents were stopped. One patient with pneumonia caused by susceptible Acinetobacter calcoaceticus subsp. anitratus initially improved and no longer required mechanical ventilation. However he subsequently deteriorated, and a resistant (12 mm) strain of the same species grew from his blood. In the last instance (patient 31), E. cloacae isolated from a joint became resistant during therapy (reduction of zone size from 30 mm to no inhibition) and was associated with unequivocal clinical failure requiring other antibiotics for cure.
Toxicity. (2) .
Success is of interest because ceftriaxone was administered only twice a day to patients with serious infections. Indeed, our patients had therapeutic serum levels with twice daily dosing. Even trough levels exceeded the MICs of most bacterial pathogens (5). Peak and trough serum ceftriaxone levels resembled those obtained by others (2, 6) . This was reassuring, since early studies, done on normal volunteers, showed concentration-dependent protein binding (9) , a phenomenon that might be altered in a debilitated population. The relatively long half-life of ceftriaxone would facilitate two types of studies modifying the dosing regimen: (i) more frequent dosing to determine whether cephalosporin levels continuously exceeding MICs enhance efficacy (4); and (ii) less frequent dosing to determine whether the frequency of drug administration can be minimized and outpatient VOL. 23, 1983 on October 26, 2017 by guest http://aac.asm.org/ Downloaded from therapy promoted. The relatively high cerebrospinal fluid levels achieved in one patient suggest that ceftriaxone may be effective in the treatment of meningitis caused by a variety of bacteria. Our patient's cerebrospinal fluid concentrations of ceftriaxone exceeded the MICs for S. pneumoniae, Neisseria meningitidis, and H. influenzae by more than 100-fold (5). In two cases of clinical and bacteriological failure (patients 7 and 31), plasma levels of ceftriaxone exceeded the MICs of the infecting organisms. The tendency for day 4 levels to exceed day 1 levels may reflect the time needed to reach steady state (7) .
Ceftriaxone was found to be very safe in our population of elderly, debilitated individuals with serious underlying disease. The contributory role of ceftriaxone in patients with hematological abnormalities and C. difficile toxinassociated diarrhea remains unclear since other host and drug-related factors may have contributed. It is intriguing, however, that all three patients with antibiotic-related diarrhea received higher doses of ceftriaxone than individuals in whom diarrhea did not occur. It is possible that the diarrhea is a dose-related phenomenon and does not occur in patients receiving relatively low doses of ceftriaxone.
Emergence of resistance during treatment with expanded spectrum cephalosporins raises much concern (8) . However, we documented emergence of resistance in only 4 of 31 gramnegative rod isolates by using disk zone size criteria. These may represent superinfection with resistant organisms or induction of resistance in the flora present at the onset of therapy. In only two of these episodes was it associated with clinical failure. Whether it is an uncommon event or a frequent menace to the seriously ill deserves more study. None of our patients on this expanded-spectrum cephalosporin developed an enterococcal superinfection (10) .
In view of the relative safety, unique pharmacokinetic properties, and excellent clinical and bacteriological efficacy of ceftriaxone in this debilitated adult population, additional clinical studies with this promising antibiotic are indicated.
